AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 41 min read$SYRE

Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90

Spyre Therapeutics (SYRE) officer Heidy King-Jones exercised options for 28,399 shares at $14.50 each and sold them at prices up to $90.00, following a pre-arranged Rule 10b5-1 plan. The sales occurred on September 1-2, 2026, with weighted-average prices ranging from $85.71 to $88.69. Gross proceeds totaled approximately $2.48 million, with a pre-tax spread of about $2.07 million.

Original reporting
stocktitan.net
Published Sep 4, 2026, 2:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 4:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SYRE
Neutral
medium confidence
Mentioned
$SYRE
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SYRENeutralLow
01

Why it matters

The Form 4 filing provides the first public detail of the officer's option exercise and sale, offering a fresh data point for traders.

02

Market read

Routine insider transaction; limited immediate trading relevance but useful for monitoring insider trends.

03

What to watch

Potential upcoming clinical data releases could offset any negative perception from the sale.

Relevance 4/10Novelty 4/10Timing: Sept 1‑2 2026 (same‑day filing)

Background

Spyre Therapeutics (SYRE) is a biotech firm that recently completed a 1‑for‑25 reverse stock split in 2023.

Company-level read

Ticker impact

$SYRENeutralMedium confidence
Context

Officer Heidy King-Jones exercised 28,399 options at $14.50 and sold the shares at $85.71‑$90 under a Rule 10b5‑1 plan.

Expected impact

Potential short‑term downward pressure of 1‑2% if market perceives insider selling as negative.

Evidence & confidence

Sale size is modest and disclosed via a primary Form 4 filing; traders may watch for any follow‑on insider activity.

Market effects

Sector

Minimal; reflects typical insider liquidity events in biotech sector.

Regional

US biotech market only; no broader regional effect.

Global

Low; isolated to Spyre Therapeutics.

Counterpoint

What could challenge this read

Insider sales can be routine; the price may remain unchanged if broader market sentiment stays positive.

Key entities

  • Officer
    Heidy King-Jones

    Executed options and sold shares under a Rule 10b5‑1 plan.

Read at source← All news

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

investing.com2 min